Roth MKM last night initiated coverage of Longeveron (LGVN) with a Buy rating and $10 price target The firm says its investment thesis is driven by the 100% transplant-free survival benefits at the end of five years delivered by Lomecel-B in hypoplastic left heart syndrome. HLHS presents a grave danger to infant survival despite three-stage palliative surgeries, As previously reported,
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on LGVN:
- Longeveron initiated with a Buy at Roth MKM
- Longeveron reports Q3 EPS (34c), consensus (44c)
- Longeveron appoints Blass as Chief Technology Officer
- Longeveron Inc. (LGVN) Q3 Earnings Cheat Sheet
- Longeveron presents Lomecel-B long-term transplant-free survival data in HLHS
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
